Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune, Inovio enter into strategic cancer vaccine collaboration
As part of the deal, MedImmune will have exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18 that are
As part of the deal, MedImmune will have exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18 that are
The Phase I trials will evaluate the safety and efficacy of both investigative agents separately combined with an anti-PD-1 therapy Keytruda in these patients. Merck’s Keytruda is a
XCITE is an FDA fast tracked, pivotal Phase III trial of the company’s cancer drug Xilonix. XCITE is designed to assess improvement in overall survival of patients in
IGN002 is genetically engineered by fusing an antibody with interferon, a protein that plays a major role in regulating the immune system. The approved IND will allow Valor,
Compared to the existing standard of care chemotherapy ‘docetaxel’, the company noted that nivolumab is expected to offer significant superiority in survival rates. The approval of nivolumab, a
NICE has issued a final appraisal determination (FAD) for Lixiana to help patients with a heart flutter who have an increased risk of stroke. The draft guidance states
The money, which will be given over a five-year period, will help fund a program of six to eight research projects looking at new strategies to develop new
Following completion of the acquisition, the combined company will operate under the name Chiltern and will gain global reach mostly in China and Japan. It will also provide
The company noted that beta cells play a major role in the pathogenesis of diabetes, which currently affects 387 million patients across the world. Under the deal, beta
As part of the deal, HCI awarded LSKB global rights in all therapeutic indications of HCI-1401. Developed by HCI’s Center for investigational therapeutics, HCI-1401 was selectively designed to